Doing now what patients need next
:quality(90)/)
We are Roche
A healthier future. It’s what drives us to innovate.
To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.
Creating a world where we all have more time with the people we love.
That’s what makes us Roche.
In the spotlight
:quality(90)/)
:quality(90)/)
For Investors
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
We will prevent diseases by identifying high-risk patients early to enable timely use of medicines.
:quality(90)/)
We will stop diseases by accurately diagnosing and stratifying patients to halt disease progression through targeted medicines.
:quality(90)/)
We will cure diseases by identifying the cause of disease in order to restore health through curative medicines.
:quality(90)/)
:quality(90)/)
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
Basel, 2 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, in addition to CE IVDR certification.
:quality(90)/)
Roche Accessibility Statement
At Roche, we are committed to ensuring that our websites and digital resources are accessible to all users.
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)